Chapter 17: Antianxiety Drugs in Psychiatric Care

Antianxiety Drugs in Psychiatric Care guide to antianxiety pharmacotherapy explores the evolution, mechanism, and clinical application of anxiolytic medications as detailed in Chapter 17 of Psychiatric Nursing. The discussion begins with the historical progression from early sedatives like alcohol and barbiturates to the revolution brought about by benzodiazepines in the 1950s. A significant portion of the text is dedicated to the pharmacodynamics of benzodiazepines, explaining how these agents function as central nervous system depressants by binding to specific allosteric sites on GABA-A receptors. This binding enhances the inhibitory effects of gamma-aminobutyric acid (GABA), opening chloride channels to hyperpolarize neurons and effectively slow down neuronal firing, acting as a brake on the brain's arousal systems. The summary details the pharmacokinetic distinctions among various benzodiazepines, particularly the crucial difference between drugs that require hepatic oxidation, such as diazepam and chlordiazepoxide, and those metabolized via conjugation, like lorazepam and oxazepam. This distinction is highlighted as a vital consideration for geriatric care, as aging livers struggle with oxidation, making conjugation-dependent drugs safer for older adults to prevent toxic accumulation. Clinical management issues are thoroughly examined, including the risks of tolerance, physiological dependence, and the potential for severe withdrawal symptoms if medication is stopped abruptly. The text also covers the management of benzodiazepine overdose using the receptor antagonist flumazenil, noting the associated risks of seizures and the need for ongoing monitoring due to its short half-life. Beyond benzodiazepines, the chapter evaluates buspirone, a non-benzodiazepine agent that acts as a partial serotonin agonist, offering anxiolytic benefits without sedation, abuse potential, or withdrawal risks, though with a delayed onset of action. The narrative further establishes Selective Serotonin Reuptake Inhibitors (SSRIs) and antidepressants like venlafaxine as the modern first-line treatments for long-term anxiety management, including Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), and Post-Traumatic Stress Disorder (PTSD). Finally, the review addresses adjunctive therapies, such as the use of beta-blockers like propranolol for social phobia and somatic symptoms, antihistamines like hydroxyzine, and anticonvulsants like gabapentin, providing a holistic view of the pharmacological toolkit available for treating anxiety spectrum disorders.